GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Upper GI Tract/Infantile Hypertrophic Pyloric Stenosis (IHPS)
53

Infantile Hypertrophic Pyloric Stenosis (IHPS)

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated April 1, 2025

Infantile Hypertrophic Pyloric Stenosis (IHPS): A Comprehensive Overview

Infantile Hypertrophic Pyloric Stenosis (IHPS) is a condition in infants that involves abnormal thickening (hypertrophy) of the pyloric muscle, which functions as a valve between the stomach and the duodenum (the first part of the small intestine). This thickening leads to gastric outlet obstruction, making it difficult for food to pass from the stomach into the intestines. As a result, affected infants experience severe, non-bilious projectile vomiting, which progressively worsens if left untreated. IHPS is one of the most common causes of gastrointestinal obstruction in infants and requires prompt medical attention.


Epidemiology

  • Incidence: IHPS occurs in approximately 3 in 1,000 live births in the United States, with variations in incidence globally (ranging from 1 to 8 in 1,000 live births).
  • Gender: Males are 4–5 times more likely to develop IHPS compared to females.
  • Ethnicity: The condition is most common in Caucasian infants, particularly those of Northern European descent, while it is less common in African American and Asian infants.
  • Age of Onset: Symptoms typically appear between 3–6 weeks of age and rarely occur after 12 weeks.
  • Familial Tendency: IHPS often runs in families, suggesting a polygenic inheritance pattern. Male relatives of affected females have a particularly high risk.

Causes and Risk Factors

The exact cause of IHPS is not fully understood, but it is believed to result from a combination of genetic and environmental factors.

Genetic Factors:

  • IHPS exhibits familial clustering, indicating a genetic predisposition.
  • Specific genetic loci have been identified, including NOS1 (12q24.2), IHPS2 (16p12-p13), and IHPS3 (11q14-q22).
  • Genome-wide association studies have implicated genes such as MBNL1 and NKX2-5 in increasing the risk of IHPS.

Environmental Factors:

  • Male sex: Males are significantly more likely to develop IHPS.
  • Firstborn status: Firstborn infants show a higher incidence of IHPS.
  • Macrolide antibiotics: Exposure to macrolide antibiotics (e.g., erythromycin) during infancy or indirectly through breastfeeding increases the risk.
  • Formula feeding: Formula-fed infants have a higher risk compared to breastfed infants.
  • Maternal factors: Advanced maternal age, smoking during pregnancy, and bottle feeding are associated with increased risk.

Pathophysiology

The hallmark of IHPS is hypertrophy and hyperplasia of the circular muscle layer of the pylorus, leading to narrowing of the pyloric canal. This narrowing causes gastric outlet obstruction, preventing food from moving into the small intestine.

Several hypotheses have been proposed to explain the underlying mechanisms:

  1. Nitric Oxide Deficiency: A localized deficiency in nitric oxide synthase, an enzyme responsible for smooth muscle relaxation, may lead to sustained contraction of the pyloric muscle.

  2. Abnormal Neural Development: Impaired neuronal innervation and reduced interstitial cells of Cajal (cells responsible for gut motility) have been implicated.

  3. Hormonal Influence: Elevated levels of hormones such as gastrin and prostaglandins may contribute to the development of pyloric muscle hypertrophy.


Clinical Features

IHPS typically presents with the following symptoms and signs:

  1. Projectile Vomiting:
  • Vomiting begins as mild regurgitation and progresses to forceful, projectile vomiting after feedings.
  • Vomitus is non-bilious, as the obstruction occurs before the duodenum where bile enters the gastrointestinal tract.
  • Occasionally, the vomitus may contain traces of blood due to irritation of the stomach lining.
  1. Feeding Difficulties:
  • Infants are often hungry after vomiting and may feed vigorously ("hungry vomiting").
  • Prolonged vomiting can lead to poor weight gain or weight loss.
  1. Dehydration:
  • Symptoms include dry mucous membranes, sunken fontanelle, decreased urine output, and lethargy.
  • Severe dehydration can lead to failure to thrive.
  1. Palpable "Olive" Mass:
  • A firm, mobile, olive-shaped mass may be felt in the right upper quadrant or epigastrium, representing the hypertrophied pylorus.
  • This is best palpated during or immediately after feeding.
  1. Visible Peristalsis:
  • Visible peristaltic waves may be observed moving from left to right across the abdomen as the stomach attempts to push food through the obstructed pylorus.

Diagnosis

The diagnosis of IHPS is based on clinical findings and imaging studies.

Laboratory Findings:

  • Electrolyte Imbalance:
  • Hypochloremic metabolic alkalosis due to the loss of hydrochloric acid from persistent vomiting.
  • Hypokalemia due to secondary loss of potassium through the kidneys.
  • Dehydration: Elevated blood urea nitrogen (BUN) and creatinine levels.

Imaging Studies:

  1. Ultrasound (Gold Standard):
  • Highly sensitive and specific for diagnosing IHPS.
  • Key findings include:
  • Pyloric muscle thickness >3–4 mm.
  • Pyloric channel length >14–20 mm.
  • "Target sign" or "donut sign" on transverse view of the pylorus.
  1. Upper Gastrointestinal (GI) Contrast Study:
  • Used when ultrasound results are inconclusive.
  • Findings include:
  • String sign: Narrowing of the pyloric canal.
  • Shoulder sign: Bulging of the hypertrophied pylorus into the antrum.

Management

The treatment of IHPS involves preoperative stabilization and surgical intervention.

Preoperative Management:

  1. Fluid and Electrolyte Replacement:
  • Intravenous (IV) fluids are administered to correct dehydration.
  • Electrolyte imbalances, such as hypochloremic metabolic alkalosis, are treated with normal saline and potassium supplementation.

Definitive Treatment:

  1. Ramstedt Pyloromyotomy:
  • This is the standard surgical procedure for IHPS.
  • A surgeon makes a longitudinal incision through the hypertrophied pyloric muscle down to the submucosa, allowing the pylorus to relax and restore normal gastric emptying.
  • The procedure can be performed laparoscopically or via an open surgical approach.

Postoperative Care:

  1. Post-Surgery Feeding:
  • Feeding is resumed 12–24 hours after surgery, starting with small, frequent feeds.
  • Most infants tolerate feeding well and recover quickly.
  1. Follow-Up:
  • Regular monitoring for any signs of complications, such as infection or delayed gastric emptying.

Complications

If untreated, IHPS can lead to serious complications:

  1. Severe Dehydration: Prolonged vomiting may result in hypovolemic shock.

  2. Electrolyte Imbalances:

  • Metabolic alkalosis can impair respiratory drive and lead to apnea.
  1. Malnutrition: Persistent vomiting can cause failure to thrive.

  2. Gastric Perforation: Rare but life-threatening due to increased intragastric pressure.


Differential Diagnosis

Conditions that can mimic IHPS include:

  1. Gastroesophageal Reflux Disease (GERD): Vomiting is non-projectile and associated with heartburn.

  2. Pylorospasm: A functional obstruction without hypertrophy, often resolves spontaneously.

  3. Duodenal Atresia/Stenosis: Causes bilious vomiting due to obstruction beyond the pylorus.

  4. Malrotation with Midgut Volvulus: Presents with bilious vomiting and requires emergency surgical intervention.

  5. Sepsis or Meningitis: May present with vomiting, lethargy, and poor feeding.


Prognosis

The prognosis for IHPS is excellent when diagnosed and treated promptly. After surgical intervention, most infants recover fully, resume normal feeding, and achieve healthy growth and development. Long-term complications are rare, though some infants may experience transient delayed gastric emptying or mild gastroesophageal reflux.


Key Points to Remember

  1. IHPS is a common cause of gastrointestinal obstruction in infants, typically presenting between 3–6 weeks of age.

  2. The hallmark symptom is non-bilious projectile vomiting and a palpable olive-shaped mass in the abdomen.

  3. Diagnosis is confirmed via ultrasound, which shows thickened and elongated pyloric muscle.

  4. Treatment involves preoperative stabilization followed by Ramstedt pyloromyotomy, which is highly effective.

  5. Early diagnosis and treatment are crucial to prevent complications such as dehydration, malnutrition, and shock.

If you have further questions or need more details, feel free to ask!

Related Q&A

54

Anorexia Nervosa and Bulimia Nervosa

Anorexia Nervosa (AN) and Bulimia Nervosa (BN) are two of the most common eating disorders, both of which involve significant disturbances in eating behavior and an intense preoccupation...

55

Refractory Helicobacter pylori infection

Refractory Helicobacter pylori Infection: A Comprehensive Overview Definition Refractory Helicobacter pylori (H. pylori) infection refers to persistent H. pylori infection despite undergoing two or more failed eradication attempts...

56

Etiology of upper gastrointestinal bleeding (UGIB) changed over recent decades

The etiology of upper gastrointestinal bleeding (UGIB) has undergone significant changes over the past few decades due to advancements in medical management and preventive strategies. UGIB, defined as...

57

Endoscopic versus surgical anti-reflux procedures for GERD

Endoscopic and surgical anti-reflux procedures are both effective treatment options for managing gastroesophageal reflux disease (GERD), but they differ significantly in terms of efficacy, safety, and patient suitability....

58

Optimal timing for endoscopic treatment in patients with GERD

The optimal timing for endoscopic treatment in patients with gastroesophageal reflux disease (GERD) should be carefully individualized based on the patient's clinical profile, response to prior treatments, and...

59

H. pylori infection in children and adolescents

Helicobacter pylori (H. pylori) infection in children and adolescents is a significant health concern due to its potential long-term impact on gastrointestinal health. This bacterial infection primarily affects...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer